Difference between revisions of "Treatment - Pharmacotherapy Overview"
(Created page with "Pharmacotherapy consists of the decision to start an agent or to refrain for the time being. While important to consider adding a medication, it is equally as important to con...") |
|||
Line 4: | Line 4: | ||
1) Antidepressants | 1) Antidepressants | ||
− | a. SSRIs – generally equivalent in efficacy | + | :a. SSRIs – generally equivalent in efficacy |
− | • paroxetine is avoided due to anticholinergic burden and medication interactions | + | ::• paroxetine is avoided due to anticholinergic burden and medication interactions |
− | • fluoxetine is helpful to avoid withdrawal in patients with nonadherence due to its long half-life | + | ::• fluoxetine is helpful to avoid withdrawal in patients with nonadherence due to its long half-life |
− | • fluvoxamine has been studied to be effective in patients with OCD | + | ::• fluvoxamine has been studied to be effective in patients with OCD |
− | b. SNRIs – if SSRI trials are failed, may consider SNRI. If there is an element of chronic pain, consider duloxetine | + | :b. SNRIs – if SSRI trials are failed, may consider SNRI. If there is an element of chronic pain, consider duloxetine |
− | c. DNRI (bupropion) – good to consider if there is an element of inattention / fatigue due to the dopaminergic quality, avoid in patients with seizure disorders | + | :c. DNRI (bupropion) – good to consider if there is an element of inattention / fatigue due to the dopaminergic quality, avoid in patients with seizure disorders |
− | d. TCAs – this category has greater anticholinergic burden, though nortriptyline and amitriptyline may be helpful in patients with chronic headaches; clomipramine has been studied to be effective in patients with OCD | + | :d. TCAs – this category has greater anticholinergic burden, though nortriptyline and amitriptyline may be helpful in patients with chronic headaches; clomipramine has been studied to be effective in patients with OCD |
− | e. MAOIs – generally avoided due to diet restrictions and medication interactions | + | :e. MAOIs – generally avoided due to diet restrictions and medication interactions |
2) Anxiolytics | 2) Anxiolytics | ||
− | a. SSRIs and SNRIs – as above | + | :a. SSRIs and SNRIs – as above |
− | b. Buspirone – low side-effect profile, can be taken three times a day | + | :b. Buspirone – low side-effect profile, can be taken three times a day |
− | c. Benzodiazepines – helpful in short-term treatment of anxiety, but generally should be tapered off due to dyscognitive side-effects, increased fall risk, and generally ineffective for long-term use | + | :c. [[Benzodiazepines]] – helpful in short-term treatment of anxiety, but generally should be tapered off due to dyscognitive side-effects, increased fall risk, and generally ineffective for long-term use |
− | d. Antiadrenergics – may be a good option for anxiety and agitation in TBI patients, caution in patients with lower blood pressure or bradycardia | + | :d. Antiadrenergics – may be a good option for anxiety and agitation in TBI patients, caution in patients with lower blood pressure or bradycardia |
− | • Beta-blockers – propranolol can be used TID and eventually consolidated into once a day long-acting medication | + | ::• Beta-blockers – propranolol can be used TID and eventually consolidated into once a day long-acting medication |
− | • Clonidine | + | ::• Clonidine |
− | • Prazosin – helpful to treat PTSD associated nightmares | + | ::• Prazosin – helpful to treat PTSD associated nightmares |
− | 3) Mood stabilizers | + | 3) Mood stabilizers |
− | a. Lamotrigine – slow titration to avoid Steven Johnson Syndrome, though beneficial for bipolar depression | + | :a. Lamotrigine – slow titration to avoid Steven Johnson Syndrome, though beneficial for bipolar depression |
− | b. Lithium – beneficial for both control of mania and depression in bipolar disorder, though many side effects (weight gain, polydipsia/polyuria, thyroid dysfunction), requires blood serum monitoring | + | :b. Lithium – beneficial for both control of mania and depression in bipolar disorder, though many side effects (weight gain, polydipsia/polyuria, thyroid dysfunction), requires blood serum monitoring |
− | c. Valproic acid – beneficial for control of mania or in agitation; not helpful for depression, should not be | + | :c. Valproic acid – beneficial for control of mania or in agitation; not helpful for depression, should not be avoided in women of childbearing age |
− | d. Carbamazepine – beneficial for control of mania; not helpful for depression, many medication interactions, should not be given to women of childbearing age | + | :d. Carbamazepine – beneficial for control of mania; not helpful for depression, many medication interactions, should not be given to women of childbearing age |
− | e. Antipsychotics – have mood stabilizing properties | + | :e. Antipsychotics – have mood stabilizing properties |
− | 4) Antipsychotics | + | 4) Antipsychotics |
− | a. First generation – acts on dopamine | + | :a. First generation – acts on dopamine |
− | b. Second generation – acts on dopamine and serotonin | + | :b. Second generation – acts on dopamine and serotonin |
− | • Quetiapine favored by neurologists due to low dopaminergic component, however, to reach dopaminergic effects and benefit antipsychotic properties, typically doses of 400mg+ is required. It has not been shown to be effective in controlling psychosis in Parkinson disease or agitation in dementia. Also beneficial for bipolar depression | + | ::• Quetiapine favored by neurologists due to low dopaminergic component, however, to reach dopaminergic effects and benefit antipsychotic properties, typically doses of 400mg+ is required. It has not been shown to be effective in controlling psychosis in Parkinson disease or agitation in dementia. Also beneficial for bipolar depression |
− | • Clozapine is more effective in controlling psychotic symptoms though it requires weekly blood draws to monitor for possible blood dyscrasia; it also has the worst side-effect profile regarding weight gain and metabolic effects. | + | ::• Clozapine is more effective in controlling psychotic symptoms though it requires weekly blood draws to monitor for possible blood dyscrasia; it also has the worst side-effect profile regarding weight gain and metabolic effects. |
− | • Pimavanserin – no dopaminergic qualities, has been approved for treatment of Parkinson psychosis | + | ::• Pimavanserin – no dopaminergic qualities, has been approved for treatment of Parkinson psychosis |
− | • Lurasidone - shown to be beneficial for bipolar depression | + | ::• Lurasidone - shown to be beneficial for bipolar depression |
− | • Aripiprazole – partial agonist; shown to be beneficial as a potential augmenting agent for depressive disorder, long half-life | + | ::• Aripiprazole – partial agonist; shown to be beneficial as a potential augmenting agent for depressive disorder, long half-life |
Revision as of 22:52, 12 June 2021
Pharmacotherapy consists of the decision to start an agent or to refrain for the time being. While important to consider adding a medication, it is equally as important to consider reducing medication that is either ineffective or potentially causing adverse effects.
1) Antidepressants
- a. SSRIs – generally equivalent in efficacy
- • paroxetine is avoided due to anticholinergic burden and medication interactions
- • fluoxetine is helpful to avoid withdrawal in patients with nonadherence due to its long half-life
- • fluvoxamine has been studied to be effective in patients with OCD
- b. SNRIs – if SSRI trials are failed, may consider SNRI. If there is an element of chronic pain, consider duloxetine
- c. DNRI (bupropion) – good to consider if there is an element of inattention / fatigue due to the dopaminergic quality, avoid in patients with seizure disorders
- d. TCAs – this category has greater anticholinergic burden, though nortriptyline and amitriptyline may be helpful in patients with chronic headaches; clomipramine has been studied to be effective in patients with OCD
- e. MAOIs – generally avoided due to diet restrictions and medication interactions
2) Anxiolytics
- a. SSRIs and SNRIs – as above
- b. Buspirone – low side-effect profile, can be taken three times a day
- c. Benzodiazepines – helpful in short-term treatment of anxiety, but generally should be tapered off due to dyscognitive side-effects, increased fall risk, and generally ineffective for long-term use
- d. Antiadrenergics – may be a good option for anxiety and agitation in TBI patients, caution in patients with lower blood pressure or bradycardia
- • Beta-blockers – propranolol can be used TID and eventually consolidated into once a day long-acting medication
- • Clonidine
- • Prazosin – helpful to treat PTSD associated nightmares
3) Mood stabilizers
- a. Lamotrigine – slow titration to avoid Steven Johnson Syndrome, though beneficial for bipolar depression
- b. Lithium – beneficial for both control of mania and depression in bipolar disorder, though many side effects (weight gain, polydipsia/polyuria, thyroid dysfunction), requires blood serum monitoring
- c. Valproic acid – beneficial for control of mania or in agitation; not helpful for depression, should not be avoided in women of childbearing age
- d. Carbamazepine – beneficial for control of mania; not helpful for depression, many medication interactions, should not be given to women of childbearing age
- e. Antipsychotics – have mood stabilizing properties
4) Antipsychotics
- a. First generation – acts on dopamine
- b. Second generation – acts on dopamine and serotonin
- • Quetiapine favored by neurologists due to low dopaminergic component, however, to reach dopaminergic effects and benefit antipsychotic properties, typically doses of 400mg+ is required. It has not been shown to be effective in controlling psychosis in Parkinson disease or agitation in dementia. Also beneficial for bipolar depression
- • Clozapine is more effective in controlling psychotic symptoms though it requires weekly blood draws to monitor for possible blood dyscrasia; it also has the worst side-effect profile regarding weight gain and metabolic effects.
- • Pimavanserin – no dopaminergic qualities, has been approved for treatment of Parkinson psychosis
- • Lurasidone - shown to be beneficial for bipolar depression
- • Aripiprazole – partial agonist; shown to be beneficial as a potential augmenting agent for depressive disorder, long half-life